Wednesday, Sep 22, 1999

Genentech Names Levinson as New Board Chair and Announces Appointment of Two New Directors

South San Francisco, Calif. -- September 22, 1999 --

Genentech, Inc. (NYSE: DNA) announced the appointment of Arthur D. Levinson, Ph.D. as the chairman of its board of directors. The company also announced the appointment of two additional new board members, Charles A. Sanders, M.D. and Sir Mark Richmond, Ph.D., the re-election of Herbert W. Boyer, Ph.D. and the continuation of Franz B. Humer, Ph.D. and Jonathan K.C. Knowles, Ph.D. of Roche to Genentech's board of directors.

These changes follow the public offering of 22 million Genentech shares on the New York Stock Exchange after Roche exercised its option to have Genentech redeem all of its outstanding shares not owned by Roche. Under their new affiliation agreement, Genentech and Roche agreed that the board of directors would consist of one executive officer of Genentech, two members from Roche and three independent directors.

In 1995, Dr. Levinson was named president and chief executive officer and joined Genentech's board of directors. He joined Genentech in 1980 as a senior scientist and became vice president in 1989 and senior vice president in 1993. Dr. Levinson has a doctorate in biochemistry from Princeton University.

Dr. Sanders is the former chairman and chief executive officer of Glaxo, Inc. as well as a former member of Glaxo's board of directors. Before joining Glaxo, Dr. Sanders spent eight years with Squibb Corp. where he held a number of posts, including the position of vice chairman. He is past chairman of the New York Academy of Sciences and currently a member of the Institute of Medicine of the National Academy of Sciences. Dr. Sanders is a graduate of Southwestern Medical College of the University of Texas.

Sir Mark Richmond is a senior research fellow at the School of Public Policy, University College London. Previously, he was vice chancellor at the University of Manchester and professor and head of the Department of Bacteriology at the University of Bristol. Sir Mark is currently a member of the Scientific Advisory Committee of the Institute for Biotechnology, ETH, Zurich and a member of the Scientific Advisory Board of the SPP-Biotechnology, Swiss National Foundation. He received his doctorate degrees in philosophy and science from Cambridge University, England.

Dr. Boyer, one of the co-founders of Genentech, was re-elected to the board of directors. He is professor emeritus of Biochemistry and Biophysics at the University of California, San Francisco and the chairman of the board of Allergan, Inc. Dr. Boyer is responsible for demonstrating the usefulness of recombinant DNA technology to produce medicines, which laid the groundwork for the biotechnology industry's development. He is an elected member of the National Academy of Sciences and a Fellow in the American Academy of Arts & Sciences. He received his doctorate degree from the University of Pittsburgh.

Drs. Humer and Knowles will also continue to serve as board members. Dr. Humer is the chief executive officer of F. Hoffmann-La Roche, Ltd. Dr. Knowles is the head of Global Research at F. Hoffmann-La Roche, Ltd.

Genentech, Inc. is a leading biotechnology company that discovers, develops, manufactures and markets human pharmaceuticals for significant unmet medical needs. Twelve of the currently marketed biotechnology products stem from Genentech science. Genentech markets seven products directly in the United States. The company has headquarters in South San Francisco, California and is traded on the New York Stock Exchange under the symbol DNA.

# # #